# Structure–Activity Relationship and Biosafety of Linear Pentapeptide Analogs Derived from Battacin for Antimicrobial Development

**Authors:** Haixin Sun, Yujie Zhang, Guoqing Gi, Chen Yao

PMC · DOI: 10.3390/antibiotics15020208 · Antibiotics · 2026-02-13

## TL;DR

Scientists modified a natural antimicrobial peptide to create safer, more effective versions that can fight drug-resistant bacteria and biofilms.

## Contribution

The study introduces crosslinked nanostructures of modified pentapeptides with enhanced antimicrobial efficacy and biosafety.

## Key findings

- Lauric acid-modified and crosslinked lipoic acid-modified pentapeptides effectively target MRSA and biofilms.
- Modified peptides showed strong synergy with ciprofloxacin against resistant strains.
- The physical mode of action prevents resistance development in sequential passaging assays.

## Abstract

Background: Natural antimicrobial peptides (AMPs) present a promising solution to address the global threat of drug-resistant infections; however, their clinical translation is challenged by limitations in stability, cytotoxicity, and production costs. Methods: In the present study, a linear Battacin-derived peptide (DDLFD) was modified at the N-terminus with lipid chains, cinnamic acid, or lipoic acid. The lipoic acid-modified variant was further crosslinked by UV irradiation to form stable nanoparticles. The antibacterial performance against planktonic and biofilm bacteria was systematically evaluated in vitro. Results: The results demonstrated that lauric acid-modified pentapeptide (C12-5) and crosslinked lipoic acid-modified pentapeptide (cLA-5) exhibited potent and rapid-acting effects against various pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Moreover, they showed enhanced efficacy in eradicating bacterial biofilms. Biosafety assessments based on hemolysis and cytotoxicity assays indicated favorable biocompatibility profiles of cLA-5. Mechanistic investigations confirmed that the modified pentapeptides retained a membrane-targeting mode of action characteristic of natural AMPs, involving membrane depolarization and increased permeability. This physical mechanism effectively prevented the development of resistance in sequential passaging assays and showed strong synergistic effects with ciprofloxacin against ciprofloxacin-resistant strains, effectively restoring their antibiotic susceptibility. Conclusions: Together, these findings underscore the strategic potential of rational structural modification, especially the crosslinked nanostructure, in advancing engineered AMPs toward clinical application.

## Linked entities

- **Chemicals:** lauric acid (PubChem CID 3893), cinnamic acid (PubChem CID 444539), lipoic acid (PubChem CID 864), ciprofloxacin (PubChem CID 2764)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Diseases:** infections (MESH:D007239), Cytotoxicity (MESH:D064420), OM (MESH:D015433), bacterial infections (MESH:D001424), fungal (MESH:D009181), bloodstream infections (MESH:D018805), MRSA (MESH:D013203), injury to (MESH:D014947), Resistance (MESH:D060467), pneumonia (MESH:D011014), Hemolysis (MESH:D006461)
- **Chemicals:** CV (MESH:D005840), DMEM (-), PI (MESH:D011419), TIS (MESH:D014025), ZnCl2 (MESH:C016837), amino acid (MESH:D000596), 2,3-diaminopropanoic acid (MESH:C011757), fatty acid (MESH:D005227), DiSC3(5) (MESH:C012944), vinylacetic acid (MESH:C479121), trifluoroacetic acid (MESH:D014269), Phe (MESH:D010649), CO2 (MESH:D002245), Lipopeptide (MESH:D055666), daptomycin (MESH:D017576), Lipid (MESH:D008055), Trp (MESH:D014364), glutaraldehyde (MESH:D005976), KCl (MESH:D011189), DMSO (MESH:D004121), methanol (MESH:D000432), NaCl (MESH:D012965), MgCl2 (MESH:D015636), Dab (MESH:C005959), 5-methylhexanoic acid (MESH:C481311), salt (MESH:D012492), AMP (MESH:D000089882), LA (MESH:D008063), carbons (MESH:D002244), N-phenyl-1-naphthylamine (MESH:C005444), agar (MESH:D000362), Triton X-100 (MESH:D017830), ciprofloxacin (MESH:D002939), Leu (MESH:D007930), CCK-8 (MESH:D012844), H2O (MESH:D014867), CA (MESH:C029010), Peptides (MESH:D010455), acetic acid (MESH:D019342), lauric acid (MESH:C030358), methicillin (MESH:D008712), Ethanol (MESH:D000431), cholesterol (MESH:D002784)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Enterobacter cloacae (species) [taxon 550], Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Acinetobacter baumannii (species) [taxon 470], Enterococcus faecium (species) [taxon 1352], Candida albicans (species) [taxon 5476], Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090], Pseudomonas aeruginosa (species) [taxon 287], Klebsiella pneumoniae (species) [taxon 573], Brevibacillus laterosporus (species) [taxon 1465], aureus [taxon 46170]
- **Cell lines:** NCTC clone 929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0462), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), CCK-8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937389/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937389/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937389/full.md

---
Source: https://tomesphere.com/paper/PMC12937389